Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease.

Briggs AH, Belozeroff V, Feeny D.

BMC Res Notes. 2019 Jul 8;12(1):385. doi: 10.1186/s13104-019-4413-y.

2.

Oral versus Intravenous Antibiotics for Bone and Joint Infection.

Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, Lipsky BA, Hughes HC, Bose D, Kümin M, Scarborough C, Matthews PC, Brent AJ, Lomas J, Gundle R, Rogers M, Taylor A, Angus B, Byren I, Berendt AR, Warren S, Fitzgerald FE, Mack DJF, Hopkins S, Folb J, Reynolds HE, Moore E, Marshall J, Jenkins N, Moran CE, Woodhouse AF, Stafford S, Seaton RA, Vallance C, Hemsley CJ, Bisnauthsing K, Sandoe JAT, Aggarwal I, Ellis SC, Bunn DJ, Sutherland RK, Barlow G, Cooper C, Geue C, McMeekin N, Briggs AH, Sendi P, Khatamzas E, Wangrangsimakul T, Wong THN, Barrett LK, Alvand A, Old CF, Bostock J, Paul J, Cooke G, Thwaites GE, Bejon P, Scarborough M; OVIVA Trial Collaborators.

N Engl J Med. 2019 Jan 31;380(5):425-436. doi: 10.1056/NEJMoa1710926.

3.

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Robles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Segelov E, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Hughes R, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Br J Cancer. 2018 Nov;119(11):1332-1338. doi: 10.1038/s41416-018-0319-z. Epub 2018 Nov 13.

4.

Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value.

Campbell JD, Belozeroff V, Whittington MD, Rubin RJ, Raggi P, Briggs AH.

Health Aff (Millwood). 2018 Aug;37(8):1298-1305. doi: 10.1377/hlthaff.2018.0221.

PMID:
30080450
5.

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.

Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 1;12:3183-3194. doi: 10.2147/COPD.S142378. eCollection 2017.

6.

Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data.

Leyland AH, Ouédraogo S, Nam J, Bond L, Briggs AH, Gray R, Wood R, Dundas R.

Southampton (UK): NIHR Journals Library; 2017 Oct.

7.

Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.

Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O.

Diabetes Res Clin Pract. 2017 Aug;130:24-33. doi: 10.1016/j.diabres.2016.12.019. Epub 2017 Jan 23.

8.

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Rutten-van Mölken MP.

Value Health. 2017 Mar;20(3):397-403. doi: 10.1016/j.jval.2016.10.016. Epub 2017 Jan 3.

9.

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH.

Value Health. 2016 Sep - Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21.

10.
11.

Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.

Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van Mölken MPMH, Chambers M, Lomas DA.

Med Decis Making. 2017 May;37(4):440-452. doi: 10.1177/0272989X16662009. Epub 2016 Aug 2.

PMID:
27486218
12.

Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.

Becker U, Briggs AH, Moreno SG, Ray JA, Ngo P, Samanta K.

Value Health. 2016 Jun;19(4):374-82. doi: 10.1016/j.jval.2015.12.018. Epub 2016 Mar 4.

13.

Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.

Briggs AH, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van Mölken MPMH, Lomas DA.

Med Decis Making. 2017 May;37(4):469-480. doi: 10.1177/0272989X16653118. Epub 2016 Jun 17.

PMID:
27317436
14.

Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.

Williams C, Lewsey JD, Briggs AH, Mackay DF.

Med Decis Making. 2017 May;37(4):340-352. doi: 10.1177/0272989X16651869. Epub 2016 Jun 8.

15.

Bayesian Solutions for Handling Uncertainty in Survival Extrapolation.

Negrín MA, Nam J, Briggs AH.

Med Decis Making. 2017 May;37(4):367-376. doi: 10.1177/0272989X16650669. Epub 2016 Jun 8.

PMID:
27281336
16.

MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis.

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Brozek J, Calderon M, Canonica GW, Casale TB, Chavannes NH, Cox L, Chrystyn H, Cruz AA, Dahl R, De Carlo G, Demoly P, Devillier P, Dray G, Fletcher M, Fokkens WJ, Fonseca J, Gonzalez-Diaz SN, Grouse L, Keil T, Kuna P, Larenas-Linnemann D, Lodrup Carlsen KC, Meltzer EO, Mullol J, Muraro A, Naclerio RN, Palkonen S, Papadopoulos NG, Passalacqua G, Price D, Ryan D, Samolinski B, Scadding GK, Sheikh A, Spertini F, Valiulis A, Valovirta E, Walker S, Wickman M, Yorgancioglu A, Haahtela T, Zuberbier T; MASK study group*.

J Allergy Clin Immunol. 2016 Aug;138(2):367-374.e2. doi: 10.1016/j.jaci.2016.03.025. Epub 2016 Apr 23. Review.

17.

Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.

Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, Chertow GM, Belozeroff V.

Med Decis Making. 2016 Nov;36(8):965-72. doi: 10.1177/0272989X16638312. Epub 2016 Mar 17.

PMID:
26987347
18.

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH.

Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007. Epub 2015 Oct 9.

19.

Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.

Reed SD, Neilson MP, Gardner M, Li Y, Briggs AH, Polsky DE, Graham FL, Bowers MT, Paul SC, Granger BB, Schulman KA, Whellan DJ, Riegel B, Levy WC.

Am Heart J. 2015 Nov;170(5):951-60. doi: 10.1016/j.ahj.2015.08.015. Epub 2015 Aug 20.

20.

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.

Boyd KA, Jones RJ, Paul J, Birrell F, Briggs AH, Leung HY.

BMJ Open. 2015 Oct 19;5(10):e007925. doi: 10.1136/bmjopen-2015-007925. Erratum in: BMJ Open. 2016 Aug 03;6(8):e007925corr1.

Supplemental Content

Loading ...
Support Center